<DOC>
	<DOCNO>NCT01624259</DOCNO>
	<brief_summary>The purpose study assess benefit risk once-weekly dulaglutide compare once-daily liraglutide participant type 2 diabetes inadequate glycemic control metformin .</brief_summary>
	<brief_title>A Study Comparing Effect Dulaglutide With Liraglutide Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Type 2 diabetes Not optimally control diet exercise dose metformin least 1500 milligrams/day ( mg/day ) stable dose least 3 month prior first study visit Glycosylated hemoglobin ( HbA1c ) great equal 7.0 % less equal 10.0 % Accept continue treatment metformin throughout trial , require per protocol Men nonpregnant woman age great equal 18 year Stable weight ( plus minus 5 % ) great equal 3 month prior screen Body Mass Index ( BMI ) less equal 45 kilograms/square meter ( kg/m^2 ) Have type 1 diabetes mellitus Have treat ANY antihyperglycemic medication ( metformin ) time first study visit within 3 month prior first study visit Have use insulin therapy ( outside pregnancy ) time past 2 year , except shortterm treatment acute condition , maximum 4 week ; insulin use within 3 month prior first study visit Have treat drug promote weight loss within 3 month first study visit Are receive chronic ( great 14 day ) systemic glucocorticoid therapy receive therapy within 4 week immediately prior first study visit Have follow cardiovascular condition within 2 month prior first study visit : acute myocardial infarction , New York Heart Association Class III Class IV heart failure , cerebrovascular accident Have know clinically significant gastric empty abnormality ( , severe diabetic gastroparesis gastric outlet obstruction ) undergone gastric bypass ( bariatric ) surgery restrictive bariatric surgery Have acute chronic hepatitis , sign symptoms liver disease , alanine transaminase level great equal 3 time upper limit normal Have history chronic pancreatitis acute idiopathic pancreatitis diagnose type acute pancreatitis within 3 month period prior first study visit Have serum creatinine great equal 1.5 milligrams/deciliter ( mg/dL ) ( male ) great equal 1.4 mg/dL ( female ) , creatinine clearance le 60 milliliters/minute ( mL/minute ) Have self family history type 2A type 2B multiple endocrine neoplasia ( MEN 2A 2B , respectively ) absence know Ccell hyperplasia ( exclusion include participant family history MEN 2A 2B whose family history syndrome Rearranged Transfection ( RET ) negative ; exception exclusion participant whose family member MEN 2A 2B know RET mutation potential participant study negative RET mutation ) Have self family history medullary Ccell hyperplasia , focal hyperplasia , carcinoma ( include sporadic , familial , part MEN 2A 2B syndrome ) Have serum calcitonin great equal 20 picograms/milliliter ( pg/mL )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>